Avadel Pharmaceuticals plc [NASDAQ: AVDL] closed the trading session at $15.47.
The stocks have a year to date performance of 9.56 percent and weekly performance of 19.00 percent. The stock has been moved at -15.46 percent over the last six months. The stock has performed 18.45 percent around the most recent 30 days and changed -5.27 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 876.84K shares, AVDL reached to a volume of 5112072 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Avadel Pharmaceuticals plc [AVDL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVDL shares is $24.27 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVDL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Rodman & Renshaw have made an estimate for Avadel Pharmaceuticals plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 12, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price from $27 to $29. The new note on the price target was released on March 05, 2024, representing the official price target for Avadel Pharmaceuticals plc stock. Previously, the target price had yet another raise from $20 to $22, while Needham kept a Buy rating on AVDL stock. On March 05, 2024, analysts increased their price target for AVDL shares from 21 to 25.
The Average True Range (ATR) for Avadel Pharmaceuticals plc is set at 0.71, with the Price to Sales ratio for AVDL stock in the period of the last 12 months amounting to 15.65. The Price to Book ratio for the last quarter was 21.17, with the Price to Cash per share for the same quarter was set at 0.74.
AVDL stock trade performance evaluation
Avadel Pharmaceuticals plc [AVDL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.00. With this latest performance, AVDL shares gained by 18.45% in over the last four-week period, additionally sinking by -15.46% over the last 6 months – not to mention a rise of 56.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVDL stock in for the last two-week period is set at 71.04, with the RSI for the last a single of trading hit 78.72, and the three-weeks RSI is set at 64.74 for Avadel Pharmaceuticals plc [AVDL]. The present Moving Average for the last 50 days of trading for this stock 13.74, while it was recorded at 13.40 for the last single week of trading, and 15.25 for the last 200 days.
Avadel Pharmaceuticals plc [AVDL]: An insightful look at the core fundamentals
Avadel Pharmaceuticals plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.52 and a Current Ratio set at 2.82.
Earnings per share (EPS) analysis for Avadel Pharmaceuticals plc [AVDL] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVDL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Avadel Pharmaceuticals plc go to 15.00%.
Avadel Pharmaceuticals plc [AVDL]: Institutional Ownership
There are presently around $80.00%, or 84.01%% of AVDL stock, in the hands of institutional investors. The top three institutional holders of AVDL stocks are: VIVO CAPITAL, LLC with ownership of 3.97 million shares, which is approximately 4.332%. TRI LOCUM PARTNERS LP, holding 1.19 million shares of the stock with an approximate value of $$16.72 million in AVDL stocks shares; and TRI LOCUM PARTNERS LP, currently with $$11.01 million in AVDL stock with ownership which is approximately 0.8542%.
